PharmaNutra SpA AI Stock Analysis
Want to see IT:PHN full AI Analyst Report?
PharmaNutra SpA (PHN) AI Stock Analysis
PharmaNutra SpA
(Milan:PHN)
The score is driven primarily by solid balance-sheet strength and strong recent cash generation, offset by a material red flag in TTM operating profitability (negative gross and operating margins despite positive net income). Technically the trend is positive but looks overbought, and the elevated P/E with only a modest dividend yield reduces valuation support.
PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 798.57M
- Dividend Yield
- 1.44%
- Average Volume (3M)
- 15.17K
- Price to Earnings (P/E)
- 34.6
- Beta (1Y)
- 0.42
- Revenue Growth
- 16.89%
- EPS Growth
- 32.34%
- Country
- Italy
- Employees
- 128
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
PharmaNutra SpA Business Overview & Revenue Model
Company Description
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe,...
How the Company Makes Money
PharmaNutra makes money primarily by selling nutraceutical and dietary supplement products and related formulations through two main channels: (1) sales of its own branded products to distributors, pharmacies, and other commercial partners in its ser...
PharmaNutra SpA Financial Statement Overview
Summary
Balance sheet and cash flow are solid (low leverage around 0.26x debt-to-equity, strong ROE, and strongly positive TTM operating/free cash flow). The main risk is earnings quality: TTM operating profitability deteriorated sharply (negative gross/EBIT/EBITDA margins) despite a healthy net margin, suggesting reliance on non-operating items that may be less repeatable.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 148.27M | 131.69M | 116.15M | 101.03M | 83.39M | 68.14M |
| Gross Profit | -9.50M | 29.71M | 82.79M | 48.95M | 30.17M | 32.15M |
| EBITDA | -8.18M | 34.21M | 32.01M | 26.48M | 24.61M | 19.84M |
| Net Income | 22.97M | 20.00M | 16.61M | 12.83M | 15.05M | 13.77M |
Balance Sheet | ||||||
| Total Assets | 130.92M | 125.23M | 117.47M | 112.44M | 100.16M | 71.36M |
| Cash, Cash Equivalents and Short-Term Investments | 25.12M | 30.61M | 29.10M | 25.12M | 26.86M | 33.94M |
| Total Debt | 20.02M | 20.51M | 24.27M | 28.02M | 17.73M | 6.35M |
| Total Liabilities | 55.28M | 53.99M | 55.27M | 58.04M | 49.21M | 26.27M |
| Stockholders Equity | 75.78M | 71.35M | 62.16M | 54.41M | 50.95M | 45.08M |
Cash Flow | ||||||
| Free Cash Flow | 18.98M | 16.43M | 16.25M | -1.16M | -8.69M | 15.43M |
| Operating Cash Flow | 24.98M | 19.56M | 20.50M | 12.09M | 14.47M | 20.41M |
| Investing Cash Flow | -7.47M | -3.36M | -2.21M | -14.70M | -23.71M | -5.54M |
| Financing Cash Flow | -14.87M | -13.12M | -21.59M | -516.00K | 1.89M | -1.92M |
PharmaNutra SpA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Positive. The current price of 86.00 is above the 20-day moving average (MA) of 75.05, above the 50-day MA of 74.00, and above the 200-day MA of 78.40, indicating a bullish trend. The MACD of 2.97 indicates Negative momentum. The RSI at 76.76 is Negative, neither overbought nor oversold. The STOCH value of 93.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHN.
PharmaNutra SpA Peers Comparison
Overall Rating
IT:PHN66Neutral
IT:EUK42Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:PHN | PharmaNutra SpA | 86.00 | 36.17 | 72.59% | |
| IT:GHC | Garofalo Health Care S.P.A. | 5.20 | 0.14 | 2.79% | |
| IT:ARBS | Arterra Bioscience SpA | 3.00 | 0.13 | 4.46% | |
| IT:EUK | Eukedos S.p.A. | 0.48 | -0.26 | -35.14% | |
| IT:COSMO | Farmacosmo S.P.A. | 0.41 | -0.01 | -1.67% | |
| IT:SVS | Svas Biosana S.p.A. | 8.00 | -0.47 | -5.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
